Acumen pharmaceuticals to participate in upcoming investor conferences

Newton, mass., march 10, 2025 (globe newswire) -- acumen pharmaceuticals, inc. (nasdaq: abos), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of alzheimer's disease, announced today that management will participate in webcast fireside chats at two upcoming investor conferences:
ABOS Ratings Summary
ABOS Quant Ranking